510(k) · Cleared
ClearedModification to EN-Bloc Biopsy System
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Neothermia Corporation · GEI Electrosurgical, Cutting & Coagulation & Accessories
Cleared on Aug 22, 2005 as substantially equivalent to K003190 (Neothermia Corp., 2001) and 5 other predicates after a 5-day review. Its family tree reaches back 4 generations to 1987.
- Decided
- Aug 22, 2005
- Review
- 5 days
- Class
- Class II
- Product code
- GEI
- Recalls
- None
- Predicates
- 6
Its longest line of descent runs back 4 generations to K871390 (1987). 11 ancestors in all. No later device cites it as a predicate yet.
- Root · 4 generations backK871390 Bard Biopty Biopsy SystemC.R. Bard, Inc. · 1987
- 3 generations backK963825 Auto Suture* Abbi* SystemUnited States Surgical, A Division of Tyco Healthc · 1996
- 2 generations backK983296 Auto Suture Abbi SystemUnited States Surgical, A Division of Tyco Healthc · 1999
- 1 generation backK020031 EN-Bloc Biopsy System, Models 777-110, 777-120, 770-001, 777002…Neothermia Corp. · 2002
- This deviceK052246 Modification to EN-Bloc Biopsy SystemNeothermia Corporation · 2005
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −4 | K871390 | Bard Biopty Biopsy System | C.R. Bard, Inc. | 1987 | — |
| −3 | K963825 | Auto Suture* Abbi* System | United States Surgical, A Division of Tyco Healthc | 1996 | — |
| −2 | K983296 | Auto Suture Abbi System | United States Surgical, A Division of Tyco Healthc | 1999 | — |
| −1 | K020031 | EN-Bloc Biopsy System, Models 777-110, 777-120, 770-001, 777002, 777-006… | Neothermia Corp. | 2002 | — |
| 0 (this device) | K052246 | Modification to EN-Bloc Biopsy System | Neothermia Corporation | 2005 | — |
Other ancestors by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 1999 | 2 | 0 |
| 2001 | 1 | 0 |
| 2002 | 1 | 0 |
| 2003 | 1 | 0 |
| 2004 | 1 | 0 |
| 2005 | 1 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in GEI? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new GEI device
- #1 K231790 The InMode System with the Morpheus8 Applicatorsscore 32.7 · 21 generations · no Class I recall
- #2 Held for the reportin the report
- #3 Held for the reportin the report
What was it cleared against? (6)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K003190 | EN Bloc Biopsy SystemSummary page 1…, Suite 316 Natick, Massachusetts 01760 Phone: (508) 655-7820 Facsimile: (508) 655-6239 Predicate Devices Neothermia Corp.'s en-bloc Biopsy System (K003190, K021577, K02003 1, K042170, K050737) and the Ethicon Endo-Surgery Mammotome 510(k) K030472. Intended Use The en-bloc Biopsy Sy… | 2001 |
| * | K021577 | Modification to EN-Bloc Biopsy SystemSummary page 1…16 Natick, Massachusetts 01760 Phone: (508) 655-7820 Facsimile: (508) 655-6239 Predicate Devices Neothermia Corp.'s en-bloc Biopsy System (K003190, K021577, K02003 1, K042170, K050737) and the Ethicon Endo-Surgery Mammotome 510(k) K030472. Intended Use The en-bloc Biopsy System is i… | 2002 |
| * | K020031 | EN-Bloc Biopsy System, Models 777-110, 777-120, 770-001, 777002, 777-006, 777-301, 777-302Summary page 1…Natick, Massachusetts 01760 Phone: (508) 655-7820 Facsimile: (508) 655-6239 Predicate Devices Neothermia Corp.'s en-bloc Biopsy System (K003190, K021577, K02003 1, K042170, K050737) and the Ethicon Endo-Surgery Mammotome 510(k) K030472. Intended Use The en-bloc Biopsy System is indicated t… | 2002 |
| * | K042170 | EN-Bloc Biopsy System…Summary page 1…assachusetts 01760 Phone: (508) 655-7820 Facsimile: (508) 655-6239 Predicate Devices Neothermia Corp.'s en-bloc Biopsy System (K003190, K021577, K02003 1, K042170, K050737) and the Ethicon Endo-Surgery Mammotome 510(k) K030472. Intended Use The en-bloc Biopsy System is indicated to provide… | 2004 |
| * | K050737 | Neothermia EN-Bloc Biopsy SystemSummary page 1…tts 01760 Phone: (508) 655-7820 Facsimile: (508) 655-6239 Predicate Devices Neothermia Corp.'s en-bloc Biopsy System (K003190, K021577, K02003 1, K042170, K050737) and the Ethicon Endo-Surgery Mammotome 510(k) K030472. Intended Use The en-bloc Biopsy System is indicated to provide tissue s… | 2005 |
| * | K030472 | Mammotome Biopsy System Probe & Housing, Mammotome Hand-Held SystemSummary page 1…: (508) 655-6239 Predicate Devices Neothermia Corp.'s en-bloc Biopsy System (K003190, K021577, K02003 1, K042170, K050737) and the Ethicon Endo-Surgery Mammotome 510(k) K030472. Intended Use The en-bloc Biopsy System is indicated to provide tissue samples for diagnostic sampling of breast abnormalities.… | 2003 |
What descends from it?
No later submission names this one as a predicate yet.
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- The line of descent spans 18 years and passes through 4 companies; a new generation was cleared every 3.4 years on median.
- 1 of the 11 ancestors has a recall of any class.
- 3 other devices also cite its predicate K003190.
How does its category compare?
All GEI devicesGEI Electrosurgical, Cutting & Coagulation & Accessories: FDA decisions, review times, recalls and adverse event reports over 20 years.
FDA decisions per year · GEI
52in 2025
2026 to Oct 25, outlined.
Median 510(k) review, days · GEI
113in 2025
Receipt to decision; years with fewer than 3 clearances left blank.
Recalls per year · GEI
4in 2025
Class I (14 since 2007) Class II/III not classified
Adverse event reports per year · GEI
7,592in 2025
MAUDE reports naming product code GEI, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 50 | 51 | 21 | 2,795 |
| 2008 | 61 | 71 | 19 | 2,556 |
| 2009 | 42 | 130 | 27 | 3,591 |
| 2010 | 46 | 109 | 51 | 3,377 |
| 2011 | 35 | 135 | 32 | 4,463 |
| 2012 | 39 | 133 | 30 | 5,216 |
| 2013 | 48 | 136 | 13 | 4,897 |
| 2014 | 49 | 103 | 3 | 4,908 |
| 2015 | 47 | 123 | 4 | 4,936 |
| 2016 | 64 | 108 | 3 | 5,616 |
| 2017 | 52 | 72 | 2 | 6,073 |
| 2018 | 47 | 93 | 6 | 6,545 |
| 2019 | 48 | 93 | 5 | 7,067 |
| 2020 | 59 | 105 | 1 | 6,490 |
| 2021 | 46 | 146 | 6 | 6,354 |
| 2022 | 55 | 150 | 49 | 6,103 |
| 2023 | 65 | 104 | 27 (4) | 7,176 |
| 2024 | 59 | 125 | 22 (10) | 7,897 |
| 2025 | 52 | 113 | 4 | 7,592 |
| 2026 | 43 | 183 | 8 | — |
What is it indicated for?
The en-bloc Biopsy System is indicated to provide tissue samples for diagnostic sampling of breast abnormalities. The en-bloc Biopsy System is intended to provide breast tissue for histologic examination with partial or complete removal of an imaged abnormality. The en-bloc Biopsy System is intended to provide breast tissue for histologic examination with partial removal of a palpable abnormality. The extent of a histologic abnormality cannot always be…
Read the full statement (205 words)
The en-bloc Biopsy System is indicated to provide tissue samples for diagnostic sampling of breast abnormalities.
The en-bloc Biopsy System is intended to provide breast tissue for histologic examination with partial or complete removal of an imaged abnormality.
The en-bloc Biopsy System is intended to provide breast tissue for histologic examination with partial removal of a palpable abnormality.
The extent of a histologic abnormality cannot always be readily determined from palpation or imaged appearance. Therefore, the extent of removal of the palpable or imaged evidence of an abnormality does not predict the extent of removal of a histologic abnormality, e.g., malignancy. When the sampled abnormality is not histologically benign, it is essential that the tissue margins be examined for completeness of removal using standard surgical procedures.
In instances when a patient presents with a palpable abnormality that has been classified as benign through clinical and/or radiological criteria (e.g., fibroadenoma, fibrocystic lesion), the en-bloc Biopsy System may also be used to partially remove such palpable lesions. Whenever breast tissue is removed, histologic evaluation of the tissue is the standard of care. When the sampled abnormality is not histologically benign, it is essential that the tissue margins be examined for completeness of removal using standard surgical procedures.
Indications for use as stated in the FDA summary.
https://510kreport.com/device/K052246 · printed Nov 6, 2026
Cite this page
510(k) Report. “K052246: Modification to EN-Bloc Biopsy System.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K052246
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026